HRP970630B1 - Hepapeptide oxytocin analogues - Google Patents

Hepapeptide oxytocin analogues

Info

Publication number
HRP970630B1
HRP970630B1 HR970630A HRP970630A HRP970630B1 HR P970630 B1 HRP970630 B1 HR P970630B1 HR 970630 A HR970630 A HR 970630A HR P970630 A HRP970630 A HR P970630A HR P970630 B1 HRP970630 B1 HR P970630B1
Authority
HR
Croatia
Prior art keywords
hepapeptide
oxytocin analogues
oxytocin
analogues
hepapeptide oxytocin
Prior art date
Application number
HR970630A
Other languages
English (en)
Inventor
Per Melin
Anders Nilsson
Jerzy A Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HRP970630A2 publication Critical patent/HRP970630A2/hr
Publication of HRP970630B1 publication Critical patent/HRP970630B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HR970630A 1996-11-26 1997-11-21 Hepapeptide oxytocin analogues HRP970630B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue

Publications (2)

Publication Number Publication Date
HRP970630A2 HRP970630A2 (en) 1998-10-31
HRP970630B1 true HRP970630B1 (en) 2002-04-30

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970630A HRP970630B1 (en) 1996-11-26 1997-11-21 Hepapeptide oxytocin analogues

Country Status (35)

Country Link
US (1) US6143722A (pt)
EP (1) EP0938496B1 (pt)
JP (1) JP3405460B2 (pt)
KR (1) KR100463132B1 (pt)
CN (1) CN1129606C (pt)
AR (1) AR008531A1 (pt)
AT (1) ATE242264T1 (pt)
AU (1) AU713424B2 (pt)
BR (1) BR9713366B1 (pt)
CA (1) CA2272990C (pt)
CZ (1) CZ299532B6 (pt)
DE (1) DE69722651T2 (pt)
DK (1) DK0938496T3 (pt)
EE (1) EE03832B1 (pt)
ES (1) ES2203823T3 (pt)
HK (1) HK1022481A1 (pt)
HR (1) HRP970630B1 (pt)
HU (1) HU228568B1 (pt)
IL (1) IL129519A (pt)
LT (1) LT4650B (pt)
LV (1) LV12350B (pt)
MY (1) MY125555A (pt)
NO (1) NO321380B1 (pt)
NZ (1) NZ336445A (pt)
PL (1) PL189292B1 (pt)
PT (1) PT938496E (pt)
RO (1) RO120772B1 (pt)
RU (1) RU2180668C2 (pt)
SE (1) SE9604341D0 (pt)
SI (1) SI20026B (pt)
SK (1) SK283800B6 (pt)
TR (1) TR199901028T2 (pt)
UA (1) UA54459C2 (pt)
WO (1) WO1998023636A1 (pt)
ZA (1) ZA9710518B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
JP4615221B2 (ja) * 2002-02-27 2011-01-19 フェリング ベスローテン フェンノートシャップ ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法
AU2003229735A1 (en) * 2002-05-02 2003-11-17 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
EP1530967B1 (en) * 2003-11-13 2006-05-03 Ferring B.V. Blister pack and solid dosage form comprising desmopressin
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
PL2260053T3 (pl) * 2008-03-31 2014-11-28 Ferring Bv Analogi oksytocyny
NO2296686T3 (pt) 2008-05-21 2014-07-12
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
KR20140014059A (ko) 2010-07-15 2014-02-05 올레그 일리치 엡쉬테인 활성화되고 강화된 형태의 항체의 효과를 증가시키는 방법
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
CN103415530A (zh) 2011-03-09 2013-11-27 Jitsubo株式会社 新型的含有非肽性交联结构的交联肽、以及该交联肽的合成方法和用于该方法的新型有机化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
WO2017060339A1 (en) 2015-10-06 2017-04-13 Ferring B.V. New methods for making barusiban and its intermediates
SG11201804789QA (en) 2016-01-04 2018-07-30 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
AU2017300026B2 (en) 2016-07-21 2023-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
LV12350B (en) 1999-11-20
CA2272990C (en) 2002-11-19
SI20026A (sl) 2000-02-29
AU5142998A (en) 1998-06-22
JP3405460B2 (ja) 2003-05-12
MY125555A (en) 2006-08-30
JP2000507617A (ja) 2000-06-20
EE9900210A (et) 1999-12-15
RU2180668C2 (ru) 2002-03-20
CZ299532B6 (cs) 2008-08-27
CA2272990A1 (en) 1998-06-04
HUP0000577A3 (en) 2001-02-28
DE69722651T2 (de) 2004-04-08
PL189292B1 (pl) 2005-07-29
NO992532D0 (no) 1999-05-26
LT4650B (lt) 2000-04-25
HUP0000577A2 (hu) 2000-11-28
NO992532L (no) 1999-05-26
KR100463132B1 (ko) 2004-12-23
SK70499A3 (en) 2000-10-09
BR9713366B1 (pt) 2010-05-18
SK283800B6 (sk) 2004-02-03
IL129519A0 (en) 2000-02-29
SE9604341D0 (sv) 1996-11-26
HRP970630A2 (en) 1998-10-31
UA54459C2 (uk) 2003-03-17
BR9713366A (pt) 2000-01-25
NZ336445A (en) 2000-06-23
DK0938496T3 (da) 2003-10-06
AR008531A1 (es) 2000-01-19
PT938496E (pt) 2003-10-31
EP0938496B1 (en) 2003-06-04
DE69722651D1 (en) 2003-07-10
IL129519A (en) 2004-09-27
AU713424B2 (en) 1999-12-02
ZA9710518B (en) 1998-06-10
RO120772B1 (ro) 2006-07-28
WO1998023636A1 (en) 1998-06-04
KR20000069045A (ko) 2000-11-25
HU228568B1 (en) 2013-04-29
CN1129606C (zh) 2003-12-03
ES2203823T3 (es) 2004-04-16
LT99052A (en) 2000-01-25
EE03832B1 (et) 2002-08-15
TR199901028T2 (xx) 1999-07-21
CZ183299A3 (cs) 2000-05-17
NO321380B1 (no) 2006-05-02
EP0938496A1 (en) 1999-09-01
US6143722A (en) 2000-11-07
HK1022481A1 (en) 2000-08-11
LV12350A (lv) 1999-09-20
ATE242264T1 (de) 2003-06-15
SI20026B (sl) 2000-06-30
CN1238781A (zh) 1999-12-15

Similar Documents

Publication Publication Date Title
HRP970630B1 (en) Hepapeptide oxytocin analogues
DE59704951D1 (en) Plättchenförmiges titandioxidpigment
HK1027968A1 (en) Aerosols
HU9700926D0 (en) Vitamine d3 analogues
EP0996458A4 (en) SANDRAMYCIN ANALOG
HK1027731A1 (en) Vacuum-cleaner
DE59707730D1 (en) Peripheralpumpe
DE59704086D1 (en) Twin-dualmode-filter
DE59703905D1 (en) Linearmotorgetriebene transportanlage
SG70116A1 (en) Air extraction
GB2333405B (en) Grommet
IL117498A0 (en) Tefillin case
DE59702027D1 (en) Bragg-modulator
GB9608180D0 (en) Phosphate analogues
AU133728S (en) Canister
DE59705556D1 (en) Peripheralpumpe
HUP9901287A3 (en) Coin-checking arrangement
AU131132S (en) Handleset
GB9713478D0 (en) Bug guard
AU131198S (en) Handleset
AU1593P (en) Songlines Telopea speciosissima
CA79582S (en) Jerkin
HU1174U (en) Case
PL332963A1 (en) Nalpha-2-(4-nitrophenylsulphonyl) ethoxycarboxylaminoacids
GB9608009D0 (en) By-product

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160928

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20171121